346 related articles for article (PubMed ID: 34705226)
1. Prevention of acute graft-versus-host disease in adult T-cell leukemia-lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation.
Inoue Y; Nishimura N; Murai M; Matsumoto M; Watanabe M; Yamada A; Izaki M; Nosaka K; Matsuoka M
Int J Hematol; 2022 Mar; 115(3):435-439. PubMed ID: 34705226
[TBL] [Abstract][Full Text] [Related]
2. Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality.
Fuji S; Inoue Y; Utsunomiya A; Moriuchi Y; Uchimaru K; Choi I; Otsuka E; Henzan H; Kato K; Tomoyose T; Yamamoto H; Kurosawa S; Matsuoka K; Yamaguchi T; Fukuda T
J Clin Oncol; 2016 Oct; 34(28):3426-33. PubMed ID: 27507878
[TBL] [Abstract][Full Text] [Related]
3. The Impact of a Humanized CCR4 Antibody (Mogamulizumab) on Patients with Aggressive-Type Adult T-Cell Leukemia-Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation.
Kawano N; Kuriyama T; Yoshida S; Kawano S; Yamano Y; Marutsuka K; Minato S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Kikuchi I
J Clin Exp Hematop; 2017; 56(3):135-144. PubMed ID: 28331127
[TBL] [Abstract][Full Text] [Related]
4. Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease.
Sugio T; Kato K; Aoki T; Ohta T; Saito N; Yoshida S; Kawano I; Henzan H; Kadowaki M; Takase K; Muta T; Miyawaki K; Yamauchi T; Shima T; Takashima S; Mori Y; Yoshimoto G; Kamezaki K; Takenaka K; Iwasaki H; Ogawa R; Ohno Y; Eto T; Kamimura T; Miyamoto T; Akashi K
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1608-1614. PubMed ID: 27220263
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide treatment for recurrent adult T-cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation.
Tanaka T; Inamoto Y; Ito A; Watanabe M; Takeda W; Aoki J; Kim SW; Fukuda T
Hematol Oncol; 2023 Aug; 41(3):389-395. PubMed ID: 36513602
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment with mogamulizumab followed by allogeneic hematopoietic stem-cell transplantation in adult T-cell leukemia/lymphoma: a report of two cases.
Tsubokura Y; Satake A; Hotta M; Yoshimura H; Fujita S; Azuma Y; Nakanishi T; Nakaya A; Ito T; Ishii K; Nomura S
Int J Hematol; 2016 Dec; 104(6):744-748. PubMed ID: 27573760
[TBL] [Abstract][Full Text] [Related]
7. Prediction of the risk for graft
Kamada Y; Arima N; Hayashida M; Nakamura D; Yoshimitsu M; Ishitsuka K
Leuk Lymphoma; 2022 Jul; 63(7):1701-1707. PubMed ID: 35225126
[TBL] [Abstract][Full Text] [Related]
8. Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.
Sakamoto H; Itonaga H; Sawayama Y; Furumoto T; Fujioka M; Chiwata M; Toriyama E; Kasai S; Nakashima J; Horai M; Kato T; Sato S; Ando K; Taguchi J; Imaizumi Y; Yoshida S; Hata T; Moriuchi Y; Miyazaki Y
Hematol Oncol; 2020 Apr; 38(2):162-170. PubMed ID: 31922287
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis.
Lechowicz MJ; Smith C; Ristuccia R; Dwyer K
Int J Hematol; 2024 Jun; 119(6):736-744. PubMed ID: 38532079
[TBL] [Abstract][Full Text] [Related]
10. Complete response following toxic epidermal necrolysis in relapsed adult T cell leukemia/lymphoma after haploidentical stem cell transplantation.
Morishige S; Nishi M; Saruta H; Arakawa F; Yamasaki Y; Oya S; Nakamura T; Seki R; Yamaguchi M; Aoyama K; Mouri F; Osaki K; Ohshima K; Nagafuji K
Int J Hematol; 2019 Oct; 110(4):506-511. PubMed ID: 31152415
[TBL] [Abstract][Full Text] [Related]
11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
12. Plasma exchange eliminates residual mogamulizumab but does not warrant prompt recovery of peripheral Treg levels.
Sugiura H; Matsuoka KI; Sando Y; Meguri Y; Ikegawa S; Nakamura M; Iwamoto M; Yoshioka T; Asano T; Kondo E; Fujii K; Fujii N; Maeda Y
Transfus Apher Sci; 2019 Aug; 58(4):472-474. PubMed ID: 31303512
[TBL] [Abstract][Full Text] [Related]
13. HLA-haploidentical hematopoietic stem cell transplantation with low-dose thymoglobulin GVHD prophylaxis for an adult T cell leukemia/lymphoma patient treated with pretransplant mogamulizumab.
Hirosawa M; Higashi T; Iwashige A; Yamaguchi T; Tsukada J
Ann Hematol; 2017 Feb; 96(2):327-328. PubMed ID: 27766392
[No Abstract] [Full Text] [Related]
14. Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study.
Ishida T; Hishizawa M; Kato K; Tanosaki R; Fukuda T; Takatsuka Y; Eto T; Miyazaki Y; Hidaka M; Uike N; Miyamoto T; Tsudo M; Sakamaki H; Morishima Y; Suzuki R; Utsunomiya A
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1731-9. PubMed ID: 24090597
[TBL] [Abstract][Full Text] [Related]
15. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.
Liga M; Triantafyllou E; Tiniakou M; Lambropoulou P; Karakantza M; Zoumbos NC; Spyridonidis A
Biol Blood Marrow Transplant; 2013 Jan; 19(1):75-81. PubMed ID: 22871557
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma.
Ureshino H; Kusaba K; Kidoguchi K; Sano H; Nishioka A; Itamura H; Yoshimura M; Yokoo M; Shindo T; Kubota Y; Ando T; Kojima K; Sueoka E; Kimura S
Ann Hematol; 2019 Feb; 98(2):465-471. PubMed ID: 30264165
[TBL] [Abstract][Full Text] [Related]
17. Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation.
Inoue Y; Endo S; Matsuno N; Kikukawa Y; Shichijo T; Koga K; Takaki A; Iwanaga K; Nishimura N; Fuji S; Fukuda T; Nosaka K; Matsuoka M
Bone Marrow Transplant; 2019 Feb; 54(2):338-342. PubMed ID: 30116017
[No Abstract] [Full Text] [Related]
18. Successful treatment strategy in corporating mogamulizumab and cord blood transplantation in aggressive adult T-cell leukemia-lymphoma: a case report.
Nakata K; Fuji S; Koike M; Tada Y; Masaie H; Yoshida H; Watanabe E; Kobayashi S; Tojo A; Uchimaru K; Ishikawa J
Blood Cell Ther; 2020 Feb; 3(1):6-10. PubMed ID: 37465376
[TBL] [Abstract][Full Text] [Related]
19. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.
Haverkos BM; Abbott D; Hamadani M; Armand P; Flowers ME; Merryman R; Kamdar M; Kanate AS; Saad A; Mehta A; Ganguly S; Fenske TS; Hari P; Lowsky R; Andritsos L; Jagasia M; Bashey A; Brown S; Bachanova V; Stephens D; Mineishi S; Nakamura R; Chen YB; Blazar BR; Gutman J; Devine SM
Blood; 2017 Jul; 130(2):221-228. PubMed ID: 28468799
[TBL] [Abstract][Full Text] [Related]
20. Graft-versus-adult T-cell leukemia/lymphoma effect following allogeneic hematopoietic stem cell transplantation.
Yonekura K; Utsunomiya A; Takatsuka Y; Takeuchi S; Tashiro Y; Kanzaki T; Kanekura T
Bone Marrow Transplant; 2008 Jun; 41(12):1029-35. PubMed ID: 18332910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
